Vela Diagnostics Launches First CE-IVD Next-Generation Sequencing Oncology Panel for Melanoma Testing on the Automated Sentosa(R) NGS Workflow
(firmenpresse) - SINGAPORE -- (Marketwired) -- 09/29/14 -- Vela Diagnostics announced today the CE-IVD launch of the Sentosa® SQ Melanoma Panel for Next-Generation Sequencing (NGS)-based gene sequence variant detection and identification.
"Currently, between two and three million non-melanoma skin cancers and 132,000 melanoma skin cancers occur globally each year. Melanoma is the most aggressive form and is responsible for more than 75% of all skin cancer-related deaths. Recently developed therapies allow targeted treatment based on molecular changes, and this test is the first in the market that gives clinicians the opportunity to quickly and easily test a large number of treatment relevant genes for mutations," said Vela Diagnostics' CEO Michael Tillmann.
The Sentosa® SQ Melanoma Panel simultaneously detects 127 hot spot mutations and sequence variants with only minimal sample input requirement. Run on the automated Sentosa NGS system solution, DNA extraction, library preparation and comprehensive result reporting are automated. The automated reporting allows for quick DNA sequence variants identification and thus saves time and costs. The easy to interpret format includes automated bioinformatics. The Sentosa workflow also allows for seamless sample tracking and IT connectivity to ease information transfer and sample traceability.
This first NGS panel launched is part of the NGS portfolio, which will be extended by other oncology and virology panels such as for Non-Small Cell Lung Cancer (NSCLC) or Colorectal Cancer (CRC) cancer sequence variants and HCV genotyping.
The Sentosa® SQ Melanoma Panel is the first NGS-based oncology panel worldwide to be launched for diagnostic use*. With the launch of the Sentosa SQ Melanoma Panel, Vela Diagnostics is the only provider to offer an automated workflow that supports both NGS and PCR tests; currently more than 30 IVD PCR tests are available* and 7 NGS panel are planned for launch. Both workflows are flexible to be customized for open-channel capability and can easily be integrated in current laboratory workflows and IT connectivity.
* Product availability is country dependent, not available in the US.
Vela Diagnostics is a worldwide provider of PCR and NGS testing solutions that address automation, portfolio consolidation and IT interfacing for individual testing needs. Established in 2011 with its global headquarters in Singapore, Vela Diagnostics provides innovative test and data reporting solutions for Real-Time PCR and Next-Generation Sequencing. The unique ability to leverage both PCR and NGS solutions combined in one workflow to test for infectious diseases and oncologic targets answers current diagnostic questions and enables laboratories to meet tomorrow's complex diagnostic challenges, with regulatory status of products based on regional availability. Reliable and multi-purpose instruments help reduce the cost for optimal efficiency across laboratories of all sizes. With scalability and open-channel capabilities, laboratories also benefit from the flexibility and versatility of the systems available. For more information, please visit .
Vela is a trademark of Vela Holding Pte Ltd. Sentosa is a registered trademark of Vela Holding Pte Ltd in several markets including the US and the European Union.
Dr. Annina Hube
Marketing Communications Manager
+49 40 890 662231
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 29.09.2014 - 12:00 Uhr
Sprache: Deutsch
News-ID 339532
Anzahl Zeichen: 4116
contact information:
Town:
SINGAPORE
Kategorie:
Diese Pressemitteilung wurde bisher 121 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Vela Diagnostics Launches First CE-IVD Next-Generation Sequencing Oncology Panel for Melanoma Testing on the Automated Sentosa(R) NGS Workflow"
steht unter der journalistisch-redaktionellen Verantwortung von
Vela Diagnostics (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
